News

The amazing rise and shocking fall of the company that created Ozempic
A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain ...
Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Neurology Advisor6h
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.
Pharmabiz11h
Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032
Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032: San Francisco Wednesday, August 6, 2025, 14:00 Hrs [IST] Inn ...
The Manila Times23h
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health:In patients with type 2 diabetes (T2D) not achieving glycemic targets, ...